

**Staphylococcus haemolyticus - NRS69**

Other designations ( Shae 2 )

Demographic Information:			
Country/State:	United States / Kentucky	Date of Isolation:	10/06/2000
Patient Age:	22 Year(s)	Gender:	Male
Patient Location:	Inpatient	Patient Service:	Bone Marrow
Culture Source:			
Literature Citation:	N/A		
Donor Reported MIC Results (ug/ml)	Vancomycin = 4		Teicoplanin = N/A
Comment:	N/A		
Repositories:	Glycopeptide Intermediate Staphylococci		

**NARSA Antimicrobial Susceptibility Data for Glycopeptides**

Drug	Broth Microdilution		<sup>a</sup> Conventional Etest 0.5 McFarland Std		<sup>b</sup> Modified Etest 2 McFarland Std		<sup>c</sup> BHI Agar Screen	Disk Diffusion	
	µg/mL MIC <del>pg/ml</del>	CLSI Interprtn	MIC µg/ml	CLSI Interprtn	MIC µg/ml	CLSI Interprtn		Zone diam. (mm)	CLSI Interprtn
<b>Vancomycin:</b>	= 4	S	= 6	I	= 16	I	CG(24)	= 19	S
<b>Teicoplanin:</b>	= 32	R	= 96	R	= 192	R		= 9	R

S = Susceptible; R = Resistant; NS = Not Susceptible; I =Intermediate; N/A = Not Available P= Pending results

NARSA Antimicrobial Profile for Other Antimicrobial Agents			Molecular Characterization Data	
Drug	µg/mL MIC <del>(pg/ml)</del>	CLSI Interprtn	PCR	Result
<b>Ciprofloxacin</b>	= 16	R	<b>vanA</b>	NEGATIVE
<b>Clindamycin</b>	= 0.12	S	<b>vanB</b>	NEGATIVE
<b>Daptomycin</b>	= 1	N/A	<b>vanC1</b>	NEGATIVE
<b>Erythromycin</b>	> 8	R	<b>vanC2</b>	NEGATIVE
<b>Gentamicin</b>	> 16	R	<b>vanD</b>	NEGATIVE
<b>Linezolid</b>	= 0.5	S	<b>vanE</b>	NEGATIVE
<b>Oxacillin</b>	> 16	R	<b>mecA</b>	POSITIVE
<b>Penicillin</b>	> 2	R		
<b>Quinupristin/dalfopristin</b>	= 0.25	S		
<b>Trimeth/sulfa</b>	> 4/76	R		